Skip to main content

ALXO

Stock
Health Care
Biotechnology

Performance overview

ALXO Price
Price Chart

Forward-looking statistics

Beta
1.16
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Company info

SectorHealth Care
IndustryBiotechnology
Employees65
Market cap$469.4M

Fundamentals

Enterprise value
Revenue
Revenue per employee
Profit margin
Debt to equity

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)
Dividend per share
Revenue per share
Avg trading volume (30 day)
Avg trading volume (10 day)
Put-call ratio

Macro factor sensitivity

Growth+4.1
Credit+4.3
Liquidity-4.7
Inflation-0.5
Commodities-0.5
Interest Rates-1.6

Valuation

Dividend yield0.00%
PEG Ratio
Price to sales
P/E Ratio-0.19
Enterprise Value to Revenue
Price to book

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

ALX Oncology Holdings (ALXO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Investment Research (March 20, 2025)
ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation

ALX Oncology Holdings Inc (NASDAQ: ALXO) presented initial clinical data from its ongoing Phase 1 / 2 trial evaluating evorpacept combined with azacitidine for untreated higher-risk or relapsed or refractory myelodysplastic syndrome.  The new results were shared at the 63rd American Society of Hematology (ASH).

Benzinga (December 13, 2021)
Top Wall Street analysts bet on these stocks for long-term growth

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Alcon, Semtech, Upstart, and others.

CNBC (March 28, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free